

# Tanguy Y Seiwert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1398711/publications.pdf>

Version: 2024-02-01

63  
papers

10,722  
citations

172457  
29  
h-index

133252  
59  
g-index

63  
all docs

63  
docs citations

63  
times ranked

15423  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
2	Reply to "Guarantee" time bias in studies on the relationship between immune-related adverse events and antitumor activity". Cancer, 2022, 128, 2551-2552.	4.1	0
3	Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 540.	2.2	2
4	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. , 2022, 10, e004688.		34
5	Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1. Journal of Clinical Oncology, 2021, 39, 1-3.	1.6	29
6	A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncology, 2021, 114, 105171.	1.5	13
7	Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Lancet Oncology, The, 2021, 22, 413-415.	10.7	12
8	Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?. Journal of Clinical Oncology, 2021, 39, 2732-2733.	1.6	7
9	Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer, 2021, 127, 4565-4573.	4.1	24
10	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncology, 2021, 122, 105566.	1.5	10
11	Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment. Oral Oncology, 2021, 123, 105618.	1.5	12
12	Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters, 2020, 471, 49-60.	7.2	12
13	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer, 2020, 126, 3237-3243.	4.1	12
14	Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 107, 662-671.	0.8	13
15	A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer, 2020, 126, 2146-2152.	4.1	24
16	Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. Oral Oncology, 2020, 105, 104652.	1.5	60
17	Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 2019, 96, 77-88.	1.5	57
18	Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma. Quantitative Imaging in Medicine and Surgery, 2019, 9, 399-408.	2.0	13

#	ARTICLE	IF	CITATIONS
19	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). , 2019, 7, 96.		34
20	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1568813.	4.6	31
21	Variations in HPV function are associated with survival in squamous cell carcinoma. <i>JCI Insight</i> , 2019, 4, .	5.0	67
22	Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population. <i>Head and Neck</i> , 2018, 40, 784-792.	2.0	22
23	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. <i>Oral Oncology</i> , 2018, 80, 16-22.	1.5	42
24	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	12.6	1,575
25	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
26	Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). <i>Cancer Research</i> , 2018, 78, LB-339-LB-339.	0.9	34
27	A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6031-6031.	1.6	5
28	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. <i>Oncotarget</i> , 2018, 9, 3805-3814.	1.8	6
29	Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2017, 23, 4897-4907.	7.0	21
30	AHNS Series " Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. <i>Head and Neck</i> , 2017, 39, 201-205.	2.0	13
31	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	3.7	23
32	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 43-56.	2.8	105
33	IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	8.2	2,560
34	How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?. <i>Journal of Clinical Oncology</i> , 2017, 35, 2229-2231.	1.6	18
35	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	1.6	527
36	Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6009-6009.	1.6	41

#	ARTICLE	IF	CITATIONS
37	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18726-18734.	1.8	6
38	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393.	1.8	27
39	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncology</i> , 2016, 17, 956-965.	10.7	1,369
40	Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 21-29.	0.8	29
41	Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2016, 56, 62-70.	1.5	13
42	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase 1b KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
43	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	7.0	103
44	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6012-6012.	1.6	33
45	HPV-Associated Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv344.	6.3	153
46	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015, 359, 269-274.	7.2	9
47	WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Cancer Research</i> , 2015, 13, 293-304.	3.4	82
48	Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab. <i>Cancer Immunology Research</i> , 2015, 3, 567-574.	3.4	38
49	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. <i>Clinical Cancer Research</i> , 2015, 21, 870-881.	7.0	303
50	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 53-58.	1.5	26
51	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 632-641.	7.0	525
52	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2735-2743.	1.6	458
53	Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 825-831.	1.5	7
54	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	2.5	14

#	ARTICLE	IF	CITATIONS
55	MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e105919.	2.5	52
56	Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs, 2013, 31, 417-424.	2.6	75
57	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2012, 18, 2336-2343.	7.0	104
58	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research, 2009, 69, 3021-3031.	0.9	236
59	Targeting Angiogenesis in Head and Neck Cancer. Seminars in Oncology, 2008, 35, 274-285.	2.2	79
60	Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer. Journal of Clinical Oncology, 2008, 26, 1732-1741.	1.6	153
61	A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer. Clinical Cancer Research, 2007, 13, 515-522.	7.0	84
62	The chemoradiation paradigm in head and neck cancer. Nature Clinical Practice Oncology, 2007, 4, 156-171.	4.3	194
63	A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. Cancer Investigation, 2007, 25, 435-444.	1.3	10